CD274 and cancer: However, the increasing evidence in other cancers that combination with chemotherapy could improve the anti-tumor activity of programmed cell death ligand 1 (PD-L1)-targeted therapy led to the evaluation of the combination of chemotherapy and immunotherapy in patients with metastatic TNBC in the recently completed randomized phase III IMpassion130 trial with striking results.